Novo Nordisk reports 3 million Wegovy pill prescriptions
Novo Nordisk (NYSE:NVO) announced that prescriptions for the oral version of Wegovy have exceeded 3 million since the…
Beyond GLP-1, Novo eyes next-gen obesity drugs: Vikrant Shrotriya | People
Semaglutide’s patent expiry has generated enormous discussion in India. Where does Novo Nordisk stand two months…
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy®
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EUNovo…
Novo Nordisk Unveils Fresh Wegovy Data That Could Narrow Eli Lilly’s Obesity Lead
The latest data comes as Novo tries to claw back ground from Eli Lilly, whose obesity drug Zepbound…
How Novo Nordisk (NVO) Is Expanding Its Dominance in Obesity Care
Novo Nordisk A/S (NYSE:NVO) is one of the undervalued large cap stocks to buy. On April 7, Novo…
Novo Nordisk’s Wegovy® HD available now nationwide
Wegovy® HD available through 70,000+ US pharmacies, NovoCare® Pharmacy, select telehealth providers, and more Wegovy® HD further expands the offerings…
Novo Nordisk launches higher-dose Wegovy in the United States
April 7 (Reuters) – Novo Nordisk said on Tuesday that it has made a higher-dose version of its…
Breakthrough in Weight Loss: Novo Nordisk’s High-Dose Wegovy
Novo Nordisk has announced the U.S. release of a higher-dose version of their weight-loss drug, Wegovy. The…
Think Novo Nordisk Can’t Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
Novo Nordisk (NYSE: NVO) stock has fallen 28% this year as investors fear that it’s falling behind in…
Think Novo Nordisk Can’t Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
Key Points Regulators recently approved Wegovy HD, which is a higher-dose version of its popular weight loss drug.…
Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Novo Nordisk A/S Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved…
Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Novo Nordisk A/S Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved…